AstraZeneca targets one billion COVID-19 vaccines by September

pharmafile | May 21, 2020 | News story | Business Services COVID-19, Vaccine, coronavirus, coronavirus vaccine 

AstraZeneca is attempting to deliver one billion doses of coronavirus vaccine by September, which is currently being developed in collaboration with Oxford University.

The company has secured an agreement to produce the first 400 million doses of the vaccine already. British Health Secretary Matt Hancock has said if the vaccine is successful then 30 million doses could be available in the UK by September. The vaccine is known as AZD1222.

Pascal Soriot, the Chief Executive of AstraZeneca, said: “This pandemic is a global tragedy and it is a challenge for all of humanity. We need to defeat the virus together or it will continue to inflict huge personal suffering and leave long-lasting economic and social scars in every country around the world. We are so proud to be collaborating with Oxford University to turn their ground-breaking work into a medicine that can be produced on a global scale.”

“We would like to thank the US and UK governments for their substantial support to accelerate the development and production of the vaccine. We will do everything in our power to make this vaccine quickly and widely available.”

The Biomedical Advanced Research and Development Authority (BARDA) have also pledged $1 billion to its funding and development, although securing the vaccine for the UK will be the company’s first priority.

The vaccine is one of the world’s fastest in development, as various large pharmaceutical companies compete to be the first to develop a successful treatment for COVID-19.

Conor Kavanagh

Related Content


Vaxart shares topline data from phase 2 study of norovirus vaccine candidate

Vaxart has announced topline data from its phase 2 challenge study which assessed its oral …

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

Latest content